PER 1.41% 7.0¢ percheron therapeutics limited

Sarepta gene therapy study missed key target in Duchennes, page-113

  1. 1,067 Posts.
    lightbulb Created with Sketch. 498
    I'd second that.

    Also worth looking at the excellent analyst reports from Wilsons and Morgans << linked.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.